Gilead Sciences’ (GILD) new CEO Daniel O’Day is an A-list pharma veteran, one of the industry’s most successful marketers of cancer drugs, and a decent dealmaker — three qualities the struggling biotech needs to start growing again.

O’Day, the longtime Roche (RHHBY) executive most recently in charge of its pharmaceuticals group, was named Gilead’s new CEO on Monday, the company announced. He will start on March 1, 2019, and replace John Milligan, who is leaving at the end of the year after announcing his retirement in July. O’Day’s new job was reported first by the Wall Street Journal on Sunday night.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy